SAFETY DATA SHEET
according to the Hazardous Products Regulations

Grazoprevir / Elbasvir Formulation

SECTION 1. IDENTIFICATION

Product name : Grazoprevir / Elbasvir Formulation
Other means of identification : No data available

Manufacturer or supplier's details
Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
          Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations
Carcinogenicity (Inhalation) : Category 2
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Liver, Testis)

GHS label elements
Hazard pictograms :

Signal Word : Warning
Hazard Statements : H351 Suspected of causing cancer if inhaled.
                   H373 May cause damage to organs (Liver, Testis) through pro-
                   longed or repeated exposure if swallowed.

Precautionary Statements : Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read
    and understood.
P260 Do not breathe dust.
P280 Wear protective gloves, protective clothing, eye protection
    and face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical attention.

Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION-INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>Common Name/Synonym</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>No data available</td>
<td></td>
<td>9004-34-6</td>
<td>&gt;= 5 - &lt; 10 *</td>
</tr>
<tr>
<td>Grazoprevir</td>
<td>No data available</td>
<td></td>
<td>1350462-55-3</td>
<td>&gt;= 5 - &lt; 10 *</td>
</tr>
<tr>
<td>Elbasvir</td>
<td>No data available</td>
<td></td>
<td>1370468-36-2</td>
<td>&gt;= 1 - &lt; 5 *</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>Octadecanoic acid, magnesium salt (2:1)</td>
<td>557-04-0</td>
<td>&gt;= 1 - &lt; 5 *</td>
<td></td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>Titanium anhydride</td>
<td></td>
<td>13463-67-7</td>
<td>&gt;= 0.1 - &lt; 1 *</td>
</tr>
</tbody>
</table>

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice:
In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled:
If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact:
Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact:
If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed:
If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
Suspected of causing cancer if inhaled.
May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
## Protection of first-aiders

First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

## Notes to physician

Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

**Suitable extinguishing media**

- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

**Unsuitable extinguishing media**

- None known.

**Specific hazards during fire fighting**

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

**Hazardous combustion products**

- Carbon oxides
- Metal oxides
- Chlorine compounds
- Nitrogen oxides (NOx)

**Specific extinguishing methods**

- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

**Special protective equipment for fire-fighters**

- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures**

- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

**Environmental precautions**

- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

**Methods and materials for containment and cleaning up**

- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to
determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

**SECTION 7. HANDLING AND STORAGE**

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types: Strong oxidizing agents.

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Total dust)</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (respirable dust fraction)</td>
<td>3 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA EV (total dust)</td>
<td>10 mg/m³</td>
<td>CA QC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Grazoprevir</td>
<td>1350462-55-3</td>
<td>TWA</td>
<td>85 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>850 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>Elbasvir</td>
<td>1370468-36-2</td>
<td>TWA</td>
<td>150 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA EV</td>
<td>10 mg/m³</td>
<td>CA QC OEL</td>
</tr>
</tbody>
</table>
Grazoprevir / Elbasvir Formulation

TWA (Inhalable) | 10 mg/m³ | CA BC OEL
TWA (Respirable) | 3 mg/m³ | CA BC OEL
TWA (Inhalable particulate matter) | 10 mg/m³ | ACGIH
TWA (Respirable particulate matter) | 3 mg/m³ | ACGIH
Titanium dioxide 13463-67-7 TWA | 10 mg/m³ | CA AB OEL
TWA (Total dust) | 10 mg/m³ | CA BC OEL
TWA (Respirable dust fraction) | 3 mg/m³ | CA BC OEL
TWAEV (total dust) | 10 mg/m³ | CA QC OEL
TWA (Respirable particulate matter) | 2.5 mg/m³ | ACGIH

Engineering measures: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type: Particulates type
Hand protection
Material: Chemical-resistant gloves
Remarks: Consider double gloving.
Eye protection: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Grazoprevir / Elbasvir Formulation

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: powder
Color: white
Odor: No data available
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: Not applicable
Evaporation rate: Not applicable
Flammability (solid, gas): May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids): No data available
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapor pressure: Not applicable
Relative vapor density: Not applicable
Relative density: No data available
Density: No data available
Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water
Autoignition temperature : No data available
Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY
Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions
May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION
Information on likely routes of exposure
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:
Cellulose:
### Grazoprevir / Elbasvir Formulation

<table>
<thead>
<tr>
<th>Component</th>
<th>Acute oral toxicity</th>
<th>Acute inhalation toxicity</th>
<th>Acute dermal toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grazoprevir</td>
<td>LD50 (Rat): &gt; 2,000 mg/kg</td>
<td>LC50 (Rat): &gt; 5.8 mg/l</td>
<td>LD50 (Rabbit): &gt; 2,000 mg/kg</td>
</tr>
<tr>
<td>Elbasvir</td>
<td>LD50 (Rat): &gt; 2,000 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>LD50 (Rat): &gt; 2,000 mg/kg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>LD50 (Rat): &gt; 5,000 mg/kg</td>
<td>LC50 (Rat): &gt; 6.82 mg/l</td>
<td></td>
</tr>
</tbody>
</table>

**Skin corrosion/irritation**

Not classified based on available information.

**Components:**

- **Grazoprevir:**
  - Result: No skin irritation

- **Elbasvir:**
  - Species: reconstructed human epidermis (RhE)
  - Result: No skin irritation

- **Magnesium stearate:**
  - Species: Rabbit
Grazoprevir / Elbasvir Formulation

Result : No skin irritation
Remarks : Based on data from similar materials

Titanium dioxide:
Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Grazoprevir:
Species : Bovine cornea
Result : No eye irritation

Elbasvir:
Species : Bovine cornea
Result : No eye irritation

Magnesium stearate:
Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Titanium dioxide:
Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Grazoprevir:
Test Type : Local lymph node assay (LLNA)
Routes of exposure : Dermal
Result : Not a skin sensitizer.

Elbasvir:
Test Type : Local lymph node assay (LLNA)
Routes of exposure : Dermal
Species : Mouse
Result : negative
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Grazoprevir / Elbasvir Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.1</td>
<td>09/30/2023</td>
<td>76204-00026</td>
<td>04/04/2023</td>
<td>03/17/2015</td>
</tr>
</tbody>
</table>

**Magnesium stearate:**
- **Test Type:** Maximization Test
- **Routes of exposure:** Skin contact
- **Species:** Guinea pig
- **Method:** OECD Test Guideline 406
- **Result:** negative
- **Remarks:** Based on data from similar materials

**Titanium dioxide:**
- **Test Type:** Local lymph node assay (LLNA)
- **Routes of exposure:** Skin contact
- **Species:** Mouse
- **Result:** negative

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

**Cellulose:**
- **Genotoxicity in vitro:**
  - Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
  - Test Type: In vitro mammalian cell gene mutation test
  - Result: negative

**Grazoprevir:**
- **Genotoxicity in vitro:**
  - Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
  - Test Type: Chromosome aberration test in vitro
  - Result: negative

**Elbasvir:**
- **Genotoxicity in vitro:**
  - Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
  - Test Type: Chromosome aberration test in vitro
SAFETY DATA SHEET
according to the Hazardous Products Regulations

Grazoprevir / Elbasvir Formulation

Result: negative

Genotoxicity in vivo:
Test Type: In vivo micronucleus test
Species: Rat
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment:
Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:
Genotoxicity in vitro:
Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials
Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Titanium dioxide:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo:
Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Carcinogenicity
Suspected of causing cancer if inhaled.

Components:

Cellulose:
Species: Rat
Application Route: Ingestion
Exposure time: 72 weeks
Result: negative

Titanium dioxide:
Species: Rat
Application Route: inhalation (dust/mist/fume)
Exposure time: 2 Years
Method: OECD Test Guideline 453
Result: positive
Remarks: The mechanism or mode of action may not be relevant in humans.
Carcinogenicity - Assessment: Limited evidence of carcinogenicity in inhalation studies with animals.

Reproductive toxicity
Not classified based on available information.

Components:

Cellulose:
Effects on fertility: Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Grazoprevir:
Effects on fertility: Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 400 mg/kg body weight
Result: negative

Test Type: Multi-generation study
Species: Rat
Application Route: Oral
Fertility: NOAEL: 400 mg/kg body weight
Result: No effects on fertility., No effects on fetal development.

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Embryo-fetal toxicity.: NOAEL: 200 mg/kg body weight
Result: No effects on fetal development.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Embryo-fetal toxicity.: NOAEL: 200 mg/kg body weight
Result: No effects on fetal development.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Intravenous
Embryo-fetal toxicity.: NOAEL: 100 mg/kg body weight
Result: No effects on fetal development.

Elbasvir:
Effects on fertility

Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Oral
Fertility: NOAEL: 1,000 mg/kg body weight
Result: No effects on fertility.

Effects on fetal development

Test Type: Embryo-fetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No effects on early embryonic development.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No effects on early embryonic development.

Magnesium stearate:

Effects on fertility

Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on fetal development

Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Liver, Testis) through prolonged or repeated exposure if swallowed.

Components:

Grazoprevir:
Target Organs: Liver, Testis
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Cellulose:
Species: Rat
<table>
<thead>
<tr>
<th>SAFETY DATA SHEET</th>
</tr>
</thead>
<tbody>
<tr>
<td>according to the Hazardous Products Regulations</td>
</tr>
</tbody>
</table>

### Grazoprevir / Elbasvir Formulation

**NOAEL**: >= 9,000 mg/kg  
**Application Route**: Ingestion  
**Exposure time**: 90 Days

#### Grazoprevir:

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>400 mg/kg</td>
<td>Oral</td>
<td>30 Days</td>
<td>No significant adverse effects were reported</td>
</tr>
<tr>
<td>Rat</td>
<td>400 mg/kg</td>
<td>Oral</td>
<td>180 Days</td>
<td>No significant adverse effects were reported</td>
</tr>
<tr>
<td>Dog</td>
<td>15 mg/kg</td>
<td>Oral</td>
<td>270 Days</td>
<td>Liver, Blood, Bone marrow, gallbladder, spleen, Testis</td>
</tr>
<tr>
<td>Mouse</td>
<td>200 mg/kg</td>
<td>Oral</td>
<td>90 Days</td>
<td>Liver, Kidney, Blood</td>
</tr>
<tr>
<td>Dog</td>
<td>20 mg/kg</td>
<td>Oral</td>
<td>30 Days</td>
<td>Blood, Testis</td>
</tr>
<tr>
<td>Monkey</td>
<td>10 mg/kg</td>
<td></td>
<td>8 Days</td>
<td>No significant adverse effects were reported</td>
</tr>
</tbody>
</table>

#### Elbasvir:

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>1,000 mg/kg</td>
<td>Oral</td>
<td>180 d</td>
<td>No significant adverse effects were reported</td>
</tr>
<tr>
<td>Dog</td>
<td>1,000 mg/kg</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Grazoprevir / Elbasvir Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.1</td>
<td>09/30/2023</td>
<td>76204-00026</td>
<td>04/04/2023</td>
<td>03/17/2015</td>
</tr>
</tbody>
</table>

**Application Route:** Oral  
**Exposure time:** 270 d  
**Remarks:** No significant adverse effects were reported

**Magnesium stearate:**  
Species: Rat  
NOAEL: > 100 mg/kg  
Application Route: Ingestion  
Exposure time: 90 Days  
Remarks: Based on data from similar materials

**Titanium dioxide:**  
Species: Rat  
NOAEL: 24,000 mg/kg  
Application Route: Ingestion  
Exposure time: 28 Days  

Species: Rat  
NOAEL: 10 mg/m³  
Application Route: Inhalation (dust/mist/fume)  
Exposure time: 2 y

**Aspiration toxicity**  
Not classified based on available information.

**Experience with human exposure**

**Components:**

**Grazoprevir:**  
Ingestion: Symptoms: Headache, Gastrointestinal disturbance

**Elbasvir:**  
Ingestion: Symptoms: Headache, Abdominal pain, constipation, Nausea, Fatigue, muscle pain, joint pain, Dizziness, Cough, Skin irritation, rhinitis, Drowsiness, nasal congestion

### SECTION 12. ECOLOGICAL INFORMATION

**Ecotoxicity**

**Components:**

**Cellulose:**  
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Grazoprevir:**  
Toxicity to fish: LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10 mg/l  
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates:
- EC50 (Daphnia magna (Water flea)): > 10 mg/l
  - Exposure time: 48 h
  - Method: OECD Test Guideline 202
  - Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants:
- EC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l
  - Exposure time: 72 hrs
  - Method: OECD Test Guideline 201
  - Remarks: No toxicity at the limit of solubility.
  - NOEC (Pseudokirchneriella subcapitata (green algae)): 10 mg/l
    - Exposure time: 72 hrs
    - Method: OECD Test Guideline 201
    - Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity):
- NOEC (Pimephales promelas (fathead minnow)): 0.98 mg/l
  - Exposure time: 32 d
  - Method: OECD Test Guideline 210
  - Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC (Daphnia magna (Water flea)): 5 mg/l
  - Exposure time: 21 d
  - Method: OECD Test Guideline 211

Toxicity to microorganisms:
- EC50: > 1,000 mg/l
  - Exposure time: 3 h
  - Test Type: Respiration inhibition
  - Method: OECD Test Guideline 209
  - NOEC: 1.3 mg/l
    - Exposure time: 3 h
    - Test Type: Respiration inhibition
    - Method: OECD Test Guideline 209

Elbasvir:
Toxicity to fish:
- LC50 (Lepomis macrochirus (Bluegill sunfish)): > 10 mg/l
  - Exposure time: 96 h
  - Method: OECD Test Guideline 203
  - Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates:
- EC50 (Daphnia magna (Water flea)): > 10 mg/l
  - Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

LC50 (Americamysis): 7.7 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants:
EC50 (Pseudokirchneriella subcapitata (algae)): > 0.081 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.081 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity):
NOEC (Pimephales promelas (fathead minnow)): 0.0023 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
NOEC (Daphnia magna (Water flea)): 0.84 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms:
EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 271.9 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Magnesium stearate:
Toxicity to fish:
LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates:
EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants:
EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Titanium dioxide:
Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Cellulose:
Biodegradability : Result: Readily biodegradable.

Grazoprevir:
Biodegradability : Result: Not readily biodegradable.
Biodegradation: 66 %
Exposure time: 28 d

Elbasvir:
Biodegradability : Result: Not readily biodegradable.
Biodegradation: 37 %
Exposure time: 28 d

Magnesium stearate:
Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Grazoprevir:
Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 7.62

Partition coefficient: n-octanol/water : log Pow: 3.72

Elbasvir:
Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 82
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 6.54

Magnesium stearate:
Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

Components:

Grazoprevir:
Distribution among environmental compartments : log Koc: 4.01

Elbasvir:
Distribution among environmental compartments : log Koc: 5.24

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
SAFETY DATA SHEET  
according to the Hazardous Products Regulations  

Grazoprevir / Elbasvir Formulation

Version | Revision Date | SDS Number | Date of last issue | Date of first issue  
8.1     | 09/30/2023    | 76204-00026 | 04/04/2023         | 03/17/2015          

UNRTDG  
UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)  
Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

IATA-DGR  
UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Elbasvir)  
Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

IMDG-Code  
UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code  
Not applicable for product as supplied.

Domestic regulation

TDG  
UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)  
Class : 9  
Packing group : III  
Labels : 9  
ERG Code : 171  
Marine pollutant : yes(Elbasvir)

Special precautions for user  
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.
SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
CA BC OEL : Canada. British Columbia OEL
CA QC OEL : Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA : 8-hour, time-weighted average
CA AB OEL / TWA : 8-hour Occupational exposure limit
CA BC OEL / TWA : 8-hour time weighted average
CA QC OEL / TWAEV : Time-weighted average exposure value

AICl - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); IS0 - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transporta-
SAFETY DATA SHEET according to the Hazardous Products Regulations

Grazoprevir / Elbasvir Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.1</td>
<td>09/30/2023</td>
<td>76204-00026</td>
<td>04/04/2023</td>
<td>03/17/2015</td>
</tr>
</tbody>
</table>

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 09/30/2023
Date format: mm/dd/yyyy

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CA / Z8